Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis

STOCKHOLM, Dec. 9, 2019 -- (Healthcare Sales & Marketing Network) -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint as well as key secondary endpoints in the North American Phase 3 study including 365 pat... Biopharmaceuticals Moberg Pharma, terbinafine, onychomycosis, nail fungus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news